비교리스트

 카트 문의
시장보고서
상품코드
1713186

세계의 신경 바이오마커 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Neurological Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
발행일: | 리서치사: Persistence Market Research | 페이지 정보: 영문 170 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 신경 바이오마커 시장 규모는 2025년에 95억 달러에 달할 것으로 예상되며, 2025-2032년의 예측 기간 동안 10.4%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 191억 달러에 달할 것으로 예측됩니다.

신경 바이오마커는 알츠하이머병, 파킨슨병, 다발성 경화증, 외상성 뇌손상 등 다양한 신경질환의 진단, 예후, 치료 모니터링에 필수적입니다. 이러한 바이오마커는 혈액, 뇌척수액(CSF), 소변 등의 체액에 존재하며, 신경질환의 존재를 반영하는 분자 시그니처를 식별하는 데 도움을 줍니다. 신경학적 바이오마커 시장은 진단 실험실, 의료 서비스 제공업체, 연구기관, 제약회사를 대상으로 하며, 유전자 바이오마커, 단백질 바이오마커, 영상 바이오마커 등 다양한 유형의 바이오마커를 제공합니다. 시장 성장의 원동력은 신경 질환의 유병률 증가, 바이오마커 탐색의 발전, 개인 맞춤형 의료의 채택 증가입니다.

세계 신경 바이오마커 시장은 알츠하이머, 파킨슨병과 같은 신경질환의 발병률 증가, 세계 인구의 고령화에 따른 발병률 증가 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 비침습적 진단 검사에 대한 수요 증가와 신경 질환의 조기 발견 능력은 시장 확대의 또 다른 원동력이 되고 있습니다. 분자생물학, 유전체학, 단백질체학의 발전은 진단 정확도와 치료 결과를 향상시킬 수 있는 새로운 바이오마커를 발굴하는 데 기여하고 있습니다. 또한, 개인 맞춤형 의료의 채택 증가와 약물의 효능을 모니터링하기 위한 임상시험에 바이오마커를 통합하는 것도 시장 성장에 기여하고 있습니다.

유망한 성장 전망에도 불구하고, 신경계 바이오마커 시장은 바이오마커 개발 및 검사 관련 높은 비용과 관련된 문제에 직면해 있습니다. 규제 장벽과 바이오마커 검사의 표준화 부족도 큰 도전이 되고 있습니다. 또한, 신경질환의 복잡한 특성과 특히 초기 질환의 경우 환자로부터 정확한 바이오마커 데이터를 얻는 것이 어렵다는 점도 시장 침투를 더욱 복잡하게 만들고 있습니다. 또한, 특히 신흥 시장에서는 바이오마커 기반 검사에 대한 보험급여 문제가 장벽이 되어 보급을 제한하고 있습니다.

신경학적 바이오마커 시장은 정밀의료, 인공지능(AI)의 발전, 의약품 개발에서 바이오마커의 역할 증가로 인해 큰 성장 기회를 맞이하고 있습니다. 질병 발병 예측, 질병 진행 모니터링, 치료 효과 평가에 바이오마커가 적용되면서 시장 관계자들에게 새로운 길을 열어주고 있습니다. 또한, 조기 진단을 위한 비침습적이고 비용 효율적인 바이오마커를 개발할 수 있는 기회가 확대되고 있으며, 이러한 진단 도구의 혜택을 받을 수 있는 환자 집단이 크게 확대될 가능성이 있습니다. 이 역동적인 시장에서 새로운 기회를 활용하기 위해서는 전략적 파트너십, 연구 투자, 보다 효율적인 바이오마커 검사 플랫폼의 개발이 매우 중요합니다.

세계의 신경 바이오마커 시장을 조사했으며, 바이오마커별/샘플별/적응증별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 범위와 정의
  • 시장 역학
  • 거시경제 요인
  • COVID-19의 영향 분석
  • 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 신경 바이오마커 시장 전망

  • 주요 하이라이트
  • 시장 규모 분석과 예측
    • 과거 시장 규모(10억 달러) 분석, 2019년-2024년
    • 현재 시장 규모(10억 달러) 분석과 예측, 2025년-2032년
  • 세계의 신경 바이오마커 시장 전망 : 바이오마커별
    • 서론/주요 조사 결과
    • 과거 시장 규모(10억 달러) 분석, 바이오마커별, 2019년-2024년
    • 현재 시장 규모(10억 달러) 분석과 예측, 바이오마커별, 2025년-2032년
      • 프로테옴 바이오마카
      • 유전체 바이오마커
      • 신경 영상 바이오마커
      • 대사체학 바이오마커
    • 시장의 매력 분석 : 바이오마커별
  • 세계의 신경 바이오마커 시장 전망 : 샘플별
    • 서론/주요 조사 결과
    • 과거 시장 규모(10억 달러) 분석, 샘플별, 2019년-2024년
    • 현재 시장 규모(10억 달러) 분석과 예측, 샘플별, 2025년-2032년
      • 혈액
      • 혈소판
      • 뇌척수액
      • 기타
    • 시장의 매력 분석 : 샘플별
  • 세계의 신경 바이오마커 시장 전망 : 적응증별
    • 서론/주요 조사 결과
    • 과거 시장 규모(10억 달러) 분석, 적응증별, 2019년-2024년
    • 현재 시장 규모(10억 달러) 분석과 예측, 적응증별, 2025년-2032년
      • 알츠하이머병(AD)
      • 다발성 경화증(MS)
      • 파킨슨병(PD)
      • 자폐증 스펙트럼 장애(ASD)
      • 기타
    • 시장의 매력 분석 : 적응증별
  • 세계의 신경 바이오마커 시장 전망 : 최종사용자별
    • 서론/주요 조사 결과
    • 과거 시장 규모(10억 달러) 분석, 최종사용자별, 2019년-2024년
    • 현재 시장 규모(10억 달러) 분석과 예측, 최종사용자별, 2025년-2032년
      • 병원 검사실
      • 진단센터
      • 학술연구기관
      • 바이오의약품 기업
      • 프로테옴 연구실
      • 기타
    • 시장의 매력 분석 : 최종사용자별

제5장 세계의 신경 바이오마커 시장 전망 : 지역별

  • 주요 하이라이트
  • 과거 시장 규모(10억 달러) 분석, 지역별, 2019년-2024년
  • 현재 시장 규모(10억 달러) 분석과 예측, 지역별, 2025년-2032년
    • 북미
    • 유럽
    • 동아시아
    • 남아시아 및 오세아니아
    • 라틴아메리카
    • 중동 및 아프리카
    • 시장의 매력 분석 : 지역별

제6장 북미의 신경 바이오마커 시장 전망

제7장 유럽의 신경 바이오마커 시장 전망

제8장 동아시아의 신경 바이오마커 시장 전망

제9장 남아시아 및 오세아니아의 신경 바이오마커 시장 전망

제10장 라틴아메리카의 신경 바이오마커 시장 전망

제11장 중동 및 아프리카의 신경 바이오마커 시장 전망

제12장 경쟁 구도

  • 시장 점유율 분석, 2025년
  • 시장 구조
  • 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
    • Quanterix
    • Amoneta Diagnostics
    • Bio-Rad Laboratories, Inc
    • Eli Lilly and Company
    • IXICO plc
    • Biognosys
    • Revvity
    • Beckman Coulter, Inc.
    • PreOmics GmbH
    • ADx NeuroSciences NV(A Fujirebio Company)
    • Fujirebio
    • Brainomix
    • Merck KGaA
    • Bio-Techne
    • Assay Genie
    • SomaLogic Operating Co., Inc.
    • Siemens Healthineers
    • Abbott Laboratories
    • Roche Diagnostics
    • GE HealthCare
    • Imaging Endpoints

제13장 부록

LSH 25.05.13

Persistence Market Research has recently released a comprehensive report on the worldwide market for neurological biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global neurological biomarkers market from 2025 to 2032.

Key Insights:

  • Neurological Biomarkers Market Size (2025E): USD 9.5 Billion
  • Projected Market Value (2032F): USD 19.1 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 10.4%

Neurological Biomarkers Market - Report Scope:

Neurological biomarkers are vital for the diagnosis, prognosis, and treatment monitoring of various neurological diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injuries. These biomarkers can be found in biological fluids such as blood, cerebrospinal fluid (CSF), and urine, and they help in identifying molecular signatures that reflect the presence of neurological conditions. The neurological biomarkers market caters to diagnostic labs, healthcare providers, research institutions, and pharmaceutical companies, offering a range of biomarker types, including genetic biomarkers, protein biomarkers, and imaging biomarkers. Market growth is driven by increasing prevalence of neurological disorders, advancements in biomarker discovery, and the rising adoption of personalized medicine.

Market Growth Drivers:

The global neurological biomarkers market is propelled by several key factors, including the growing incidence of neurological diseases such as Alzheimer's and Parkinson's disease, which are becoming more prevalent with an aging global population. The increasing demand for non-invasive diagnostic tests and the ability to detect neurological disorders at earlier stages further drive market expansion. Advances in molecular biology, genomics, and proteomics have led to the identification of novel biomarkers that enhance diagnostic accuracy and treatment outcomes. Moreover, the increasing adoption of personalized medicine and the integration of biomarkers in clinical trials to monitor drug efficacy also contribute to the market's growth.

Market Restraints:

Despite promising growth prospects, the neurological biomarkers market faces challenges related to the high costs associated with biomarker development and testing. Regulatory hurdles and the lack of standardization in biomarker testing also pose significant challenges. Additionally, the complex nature of neurological disorders and the difficulty in obtaining accurate biomarker data from patients, particularly in the case of early-stage diseases, further complicate market penetration. The market also faces barriers in terms of reimbursement issues for biomarker-based tests, especially in emerging markets, limiting widespread adoption.

Market Opportunities:

The neurological biomarkers market presents significant growth opportunities driven by advancements in precision medicine, artificial intelligence (AI), and the increasing role of biomarkers in drug development. The application of biomarkers in predicting disease onset, monitoring disease progression, and assessing treatment responses is opening new avenues for market players. Additionally, there is a growing opportunity for the development of non-invasive and cost-effective biomarkers for early diagnosis, which could significantly expand the patient population benefiting from these diagnostic tools. Strategic partnerships, research investments, and the development of more efficient biomarker testing platforms are crucial for capitalizing on emerging opportunities in this dynamic market.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the neurological biomarkers market globally?
  • Which types of biomarkers are most commonly used in the diagnosis and monitoring of neurological diseases?
  • How are technological advancements reshaping the competitive landscape of the neurological biomarkers market?
  • Who are the key players contributing to the neurological biomarkers market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global neurological biomarkers market?

Competitive Intelligence and Business Strategy:

Leading players in the global neurological biomarkers market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to discover novel biomarkers and develop new diagnostic platforms. Collaborations with academic institutions, healthcare providers, and pharmaceutical companies help accelerate biomarker validation and commercialization. Moreover, the development of AI-driven platforms to enhance the precision of biomarker analysis and improve diagnostic workflows is also gaining traction in the market.

Key Companies Profiled:

  • Quanterix
  • Amoneta Diagnostics
  • Bio-Rad Laboratories, Inc
  • Eli Lilly and Company
  • IXICO plc
  • Biognosys
  • Revvity
  • Beckman Coulter, Inc.
  • PreOmics GmbH
  • ADx NeuroSciences NV (A Fujirebio Company)
  • Fujirebio
  • Brainomix
  • Merck KGaA
  • Bio-Techne
  • Assay Genie
  • SomaLogic Operating Co., Inc.
  • Siemens Healthineers
  • Abbott Laboratories
  • Roche Diagnostics
  • GE HealthCare
  • Imaging Endpoints

Market Segmentation:

Neurological Biomarkers Market Research Segmentation: The neurological biomarkers market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various neurological conditions.

By Biomarkers Type

  • Proteomic Biomarkers
  • Genomic Biomarkers
  • Neuroimaging Biomarkers
  • Metabolomics Biomarkers

By Sample

  • Blood
  • Plasma
  • Cerebrospinal Fluid
  • Others

By Indication

  • Alzheimer's disease (AD)
  • Multiple sclerosis (MS)
  • Parkinson's disease (PD)
  • Autism spectrum disorder (ASD)
  • Others

By End-user

  • Hospital Labs
  • Diagnostic Centers
  • Academic & Research Institutes
  • Biopharma Companies
  • Proteomic Laboratory
  • Others

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Neurological Biomarkers Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Neurological Biomarkers Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Neurological Biomarkers Market Outlook: Biomarkers
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Biomarker, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
      • 4.3.3.1. Proteomic Biomarkers
      • 4.3.3.2. Genomic Biomarkers
      • 4.3.3.3. Neuroimaging Biomarkers
      • 4.3.3.4. Metabolomics Biomarkers
    • 4.3.4. Market Attractiveness Analysis: Biomarkers
  • 4.4. Global Neurological Biomarkers Market Outlook: Sample
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Sample, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
      • 4.4.3.1. Blood
      • 4.4.3.2. Plasma
      • 4.4.3.3. Cerebrospinal Fluid
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Sample
  • 4.5. Global Neurological Biomarkers Market Outlook: Indication
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
      • 4.5.3.1. Alzheimer's Disease (AD)
      • 4.5.3.2. Multiple Sclerosis (MS)
      • 4.5.3.3. Parkinson's Disease (PD)
      • 4.5.3.4. Autism Spectrum Disorder (ASD)
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: Indication
  • 4.6. Global Neurological Biomarkers Market Outlook: End-user
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
      • 4.6.3.1. Hospital Labs
      • 4.6.3.2. Diagnostic Centers
      • 4.6.3.3. Academic & Research Institutes
      • 4.6.3.4. Biopharma Companies
      • 4.6.3.5. Proteomic Laboratory
      • 4.6.3.6. Others
    • 4.6.4. Market Attractiveness Analysis: End-user

5. Global Neurological Biomarkers Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia & Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
    • 5.3.7. Market Attractiveness Analysis: Region

6. North America Neurological Biomarkers Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Biomarker
    • 6.2.3. By Sample
    • 6.2.4. By Indication
    • 6.2.5. By End-user
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 6.4.1. Proteomic Biomarkers
    • 6.4.2. Genomic Biomarkers
    • 6.4.3. Neuroimaging Biomarkers
    • 6.4.4. Metabolomics Biomarkers
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 6.5.1. Blood
    • 6.5.2. Plasma
    • 6.5.3. Cerebrospinal Fluid
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 6.6.1. Alzheimer's Disease (AD)
    • 6.6.2. Multiple Sclerosis (MS)
    • 6.6.3. Parkinson's Disease (PD)
    • 6.6.4. Autism Spectrum Disorder (ASD)
    • 6.6.5. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 6.7.1. Hospital Labs
    • 6.7.2. Diagnostic Centers
    • 6.7.3. Academic & Research Institutes
    • 6.7.4. Biopharma Companies
    • 6.7.5. Proteomic Laboratory
    • 6.7.6. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Neurological Biomarkers Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Biomarker
    • 7.2.3. By Sample
    • 7.2.4. By Indication
    • 7.2.5. By End-user
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 7.4.1. Proteomic Biomarkers
    • 7.4.2. Genomic Biomarkers
    • 7.4.3. Neuroimaging Biomarkers
    • 7.4.4. Metabolomics Biomarkers
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 7.5.1. Blood
    • 7.5.2. Plasma
    • 7.5.3. Cerebrospinal Fluid
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 7.6.1. Alzheimer's Disease (AD)
    • 7.6.2. Multiple Sclerosis (MS)
    • 7.6.3. Parkinson's Disease (PD)
    • 7.6.4. Autism Spectrum Disorder (ASD)
    • 7.6.5. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 7.7.1. Hospital Labs
    • 7.7.2. Diagnostic Centers
    • 7.7.3. Academic & Research Institutes
    • 7.7.4. Biopharma Companies
    • 7.7.5. Proteomic Laboratory
    • 7.7.6. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Neurological Biomarkers Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Biomarker
    • 8.2.3. By Sample
    • 8.2.4. By Indication
    • 8.2.5. By End-user
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 8.4.1. Proteomic Biomarkers
    • 8.4.2. Genomic Biomarkers
    • 8.4.3. Neuroimaging Biomarkers
    • 8.4.4. Metabolomics Biomarkers
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 8.5.1. Blood
    • 8.5.2. Plasma
    • 8.5.3. Cerebrospinal Fluid
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 8.6.1. Alzheimer's Disease (AD)
    • 8.6.2. Multiple Sclerosis (MS)
    • 8.6.3. Parkinson's Disease (PD)
    • 8.6.4. Autism Spectrum Disorder (ASD)
    • 8.6.5. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 8.7.1. Hospital Labs
    • 8.7.2. Diagnostic Centers
    • 8.7.3. Academic & Research Institutes
    • 8.7.4. Biopharma Companies
    • 8.7.5. Proteomic Laboratory
    • 8.7.6. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Neurological Biomarkers Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Biomarker
    • 9.2.3. By Sample
    • 9.2.4. By Indication
    • 9.2.5. By End-user
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 9.4.1. Proteomic Biomarkers
    • 9.4.2. Genomic Biomarkers
    • 9.4.3. Neuroimaging Biomarkers
    • 9.4.4. Metabolomics Biomarkers
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 9.5.1. Blood
    • 9.5.2. Plasma
    • 9.5.3. Cerebrospinal Fluid
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 9.6.1. Alzheimer's Disease (AD)
    • 9.6.2. Multiple Sclerosis (MS)
    • 9.6.3. Parkinson's Disease (PD)
    • 9.6.4. Autism Spectrum Disorder (ASD)
    • 9.6.5. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 9.7.1. Hospital Labs
    • 9.7.2. Diagnostic Centers
    • 9.7.3. Academic & Research Institutes
    • 9.7.4. Biopharma Companies
    • 9.7.5. Proteomic Laboratory
    • 9.7.6. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Neurological Biomarkers Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Biomarker
    • 10.2.3. By Sample
    • 10.2.4. By Indication
    • 10.2.5. By End-user
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 10.4.1. Proteomic Biomarkers
    • 10.4.2. Genomic Biomarkers
    • 10.4.3. Neuroimaging Biomarkers
    • 10.4.4. Metabolomics Biomarkers
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 10.5.1. Blood
    • 10.5.2. Plasma
    • 10.5.3. Cerebrospinal Fluid
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 10.6.1. Alzheimer's Disease (AD)
    • 10.6.2. Multiple Sclerosis (MS)
    • 10.6.3. Parkinson's Disease (PD)
    • 10.6.4. Autism Spectrum Disorder (ASD)
    • 10.6.5. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 10.7.1. Hospital Labs
    • 10.7.2. Diagnostic Centers
    • 10.7.3. Academic & Research Institutes
    • 10.7.4. Biopharma Companies
    • 10.7.5. Proteomic Laboratory
    • 10.7.6. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Neurological Biomarkers Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Biomarker
    • 11.2.3. By Sample
    • 11.2.4. By Indication
    • 11.2.5. By End-user
  • 11.3. Current Market Size (US$ Bn) and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 11.4.1. Proteomic Biomarkers
    • 11.4.2. Genomic Biomarkers
    • 11.4.3. Neuroimaging Biomarkers
    • 11.4.4. Metabolomics Biomarkers
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 11.5.1. Blood
    • 11.5.2. Plasma
    • 11.5.3. Cerebrospinal Fluid
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 11.6.1. Alzheimer's Disease (AD)
    • 11.6.2. Multiple Sclerosis (MS)
    • 11.6.3. Parkinson's Disease (PD)
    • 11.6.4. Autism Spectrum Disorder (ASD)
    • 11.6.5. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 11.7.1. Hospital Labs
    • 11.7.2. Diagnostic Centers
    • 11.7.3. Academic & Research Institutes
    • 11.7.4. Biopharma Companies
    • 11.7.5. Proteomic Laboratory
    • 11.7.6. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Quanterix
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Amoneta Diagnostics
    • 12.3.3. Bio-Rad Laboratories, Inc
    • 12.3.4. Eli Lilly and Company
    • 12.3.5. IXICO plc
    • 12.3.6. Biognosys
    • 12.3.7. Revvity
    • 12.3.8. Beckman Coulter, Inc.
    • 12.3.9. PreOmics GmbH
    • 12.3.10. ADx NeuroSciences NV (A Fujirebio Company)
    • 12.3.11. Fujirebio
    • 12.3.12. Brainomix
    • 12.3.13. Merck KGaA
    • 12.3.14. Bio-Techne
    • 12.3.15. Assay Genie
    • 12.3.16. SomaLogic Operating Co., Inc.
    • 12.3.17. Siemens Healthineers
    • 12.3.18. Abbott Laboratories
    • 12.3.19. Roche Diagnostics
    • 12.3.20. GE HealthCare
    • 12.3.21. Imaging Endpoints

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제